Retatrutide News
Every article we’ve published on Retatrutide, newest first — 5 in total. Each one is sourced to primary regulatory, trial, or peer-reviewed documents and links back to the original.
Retatrutide Diabetic Ketoacidosis Case Report Involves Online Source
A single-patient report newly indexed in PubMed describes retatrutide diabetic ketoacidosis risk in a type 1 diabetes patient who bought the investigational drug online while also fighting a bacterial gut infection. It is the kind of case that surfaces when an unapproved molecule circulates faster than its clinical evidence.
Retatrutide Cardiovascular Outcomes Trial Reaches Full Enrollment
The registry entry for TRIUMPH-Outcomes, the phase 3 retatrutide cardiovascular outcomes trial, was updated on August 24 to show the study active and closed to new participants. It is the largest single trial in Eli Lilly's retatrutide program and the one that will decide whether the triple agonist can claim organ-protection benefits rather than weight loss alone.
Retatrutide Phase 3 Trial Completed in 2,335-Person Obesity Study
A ClinicalTrials.gov record updated August 21, 2026 shows Eli Lilly's largest registered retatrutide phase 3 trial completed after enrolling 2,335 participants with obesity or overweight. No outcome data has been posted to the registry yet, and retatrutide remains an investigational drug with no marketing approval anywhere.
Retatrutide Cardiovascular Risk Biomarkers Improve in New Analysis
Researchers reporting in Diabetes, Obesity & Metabolism describe improvements in retatrutide cardiovascular risk biomarkers in adults with obesity, with and without type 2 diabetes. It is the kind of result that shapes expectations for a drug still years from any approval — and it is not the same thing as an outcomes trial.
Retatrutide Grey Market Tested: Australian Study Checks Labels
A research letter in Drug and Alcohol Review reports laboratory analysis of vials sold under the retatrutide name in Australia — a direct look at what circulates in the retatrutide grey market. It lands while the compound itself is still years from any approval decision, with a 4,500-participant liver outcomes trial now recruiting.